CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 900 enrolled
Drug / intervention
Mydriatic Agent +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04805541
NCT04805541N/ACompleted

Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model

Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi·observational·Posted Mar 18, 2021·Updated Jul 15, 2024

In Brief

An observational study evaluating Color Fundus Photography, Mydriatic Agent, and 1 other intervention for Diabetic Retinopathy and 2 related conditions. Completed, enrolled 900 participants across 1 site.

Detailed Summary

The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more. At least 90% of new cases can be reduced with proper treatment and monitoring of the eyes. The longer a person has diabetes, the more likely it is to develop diabetic retinopathy. Each year in the United States, diabetic retinopathy accounts for 12% of all new cases of blindness. It is also the leading cause of blindness in people between the ages of 20 and 64. The most important complication of diabetes leading to vision loss is diabetic retinopathy. Depending on this, macular edema, bleeding into the retina and vitreous,neovascular glaucoma can cause blindness. Diabetic retinopathy (DR) is a leading cause of vision-loss globally. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one third of DR is vision-threatening DR, including diabetic macular edema (DME). Diabetic retinopathy is a retinal disease that can often be stopped with early diagnosis, but if neglected, it can lead to severe vision loss, including permanent blindness. Diabetes has high morbidity and there are millions of people who should be screened for diabetic retinopathy (DR). Annual eye screening is recommended for all diabetic patients since vision loss can be prevented if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is less than that needed to screen a growing diabetic population. Therefore, the automatic DR screening system will be able to screen more diabetic patients and diagnose them early. EyeCheckup is an automated retinal screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DR. This study is designed to assess the safety and efficacy of EyeCheckup. The study is a single center study to determine the sensitivity and specificity of EyeCheckup to diabetic retinopathy. EyeCheckup is an automated software device that is designed to analyze ocular fundus digital color photographs taken in frontline primary care settings in order to quickly screen for diabetic retinopathy (DR).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
CollaboratorsAkdeniz University

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 18, 2021
Enrollment StartFeb 1, 2022
Primary CompletionJul 4, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.3 years ago

Interventions

Color Fundus Photographyprocedure

Subjects will undergo fundus photography before and after administration of mydriatic agent.

Mydriatic Agentdrug

Subjects will be administered mydriatic medication to dilate their pupils.

EyeCheckup - AI Based DR Screeningdevice

Screening for existence of "More than mild" or "Vision-threatening" Diabetic Retinopathy, and/or Diabetic Macular Edema.